Top

CNS Drugs

Published in:

01-07-2010 | Review Article

Pharmacotherapy of bipolar disorder in children and adolescents

Recent progress

Authors: Jonathan C. Pfeifer, Robert A. Kowatch, Dr Melissa P. DelBello

Published in: CNS Drugs | Issue 7/2010

Abstract

Child and adolescent bipolar disorder (BPD) is a serious psychiatric disorder that often causes significant impairment in functioning. Pharmacological intervention is the cornerstone of treatment for bipolar youth, although psychotherapeutic interventions may be beneficial as adjunctive treatment. Medications used for the treatment of BPD in adults are still commonly used for bipolar children and adolescents. With the recent US FDA indication of risperidone, aripiprazole, quetiapine and olanzapine for the treatment of bipolar youth, the atypical antipsychotics are rapidly becoming a first-line treatment option. However, these agents are associated with adverse effects such as increased appetite, weight gain and type II diabetes mellitus. Although several evidence-based medications are now available for the treatment of BPD in younger populations, additional studies to evaluate the short- and long-term efficacy and potential for adverse events of these and other medications are needed.

McClellan J, Kowatch R, Findling RL, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(1): 107–25PubMedCrossRef

Youngstrom EA, Duax J. Evidence-based assessment of pediatric bipolar disorder, part I: base rate and family history. J Am Acad Child Adolesc Psychiatry 2005; 44(7): 712–7PubMedCrossRef

Wozniak J, Biederman J, Kwon A, et al. How cardinal are cardinal symptoms in pediatric bipolar disorder? An examination of clinical correlates. Biol Psychiatry 2005; 58(1): 583–8PubMedCrossRef

Weinberg WA, Rehmet A. Childhood affective disorder and school problems. In: Cantwell DP, Carlson GP, editors. Affective disorders in childhood and adolescence: an update. Jamaica (NY): Spectrum Publishing Inc., 1983: 109–28CrossRef

Wilens TE, Biederman J, Millstein RB, et al. Risk for substance use disorders in youths with child- and adolescentonset bipolar disorder. J Am Acad Child Adolesc Psychiatry 1999; 38(6): 680–5PubMedCrossRef

Goldstein TR, Birmaher B, Axelson D, et al. History of suicide attempts in pediatric bipolar disorder: factors associated with increased risk. Bipolar Disord 2005; 7(6): 525–35PubMedCrossRef

Chang KD. The bipolar spectrum in children and adolescents: developmental issues. J Clin Psychiatry 2008 Mar; 69(3): e9PubMedCrossRef

Leibenluft E, Charney DS, Towbin KE, et al. Defining clinical phenotypes of juvenile mania. J Am Acad Child Adolesc Psychiatry 2003; 160(3): 430–7

McClellan JM, Hamilton JD. An evidence-based approach to an adolescent with emotional and behavioral dysregulation. J Am Acad Child Adolesc Psychiatry 2006; 45(4): 489–93PubMedCrossRef

10.

The British Psychological Society and Gaskell. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG38fullguideline.pdf [Accessed 2010 Feb 17]

11.

Faraone SV, Glatt SJ, Tsuang MT. The genetics of pediatric-onset bipolar disorder. Biol Psychiatry 2003; 53(11): 970–7PubMedCrossRef

12.

DelBello MP, Adler CM, Strakowski SM. The neurophysiology of pediatric bipolar disorder. CNS Spectr 2006; 11: 298–311PubMed

13.

Pavuluri MN, Graczyk PA, Henry DB, et al. Child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: development and preliminary results. J Am Acad Child Adolesc Psychiatry 2004; 43(5): 528–37PubMedCrossRef

14.

Lam DH, McCrone P, Wright K, et al. Cost effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study. Br J Psychiatry 2005; 186: 500–6PubMedCrossRef

15.

Miklowitz DJ. The role of the family in the course and treatment of bipolar disorder. Curr Dir Psychol Sci 2007; 16(4): 192–6PubMedCrossRef

16.

Townsend LD, Demeter CA, Youngstrom E, et al. Family conflict moderates response to pharmacological intervention in pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2007; 17(6): 843–52PubMedCrossRef

17.

Kowatch RA, DelBello MP. Pharmacotherapy of children and adolescents with bipolar disorder. Psychiatr Clin North Am 2005; 28: 385–7PubMedCrossRef

18.

Vitiello B, Behar D, Malone R, et al. Pharmacokinetics of lithium carbonate in children. J Clin Psychopharmacol 1988; 8(5): 355–9PubMedCrossRef

19.

[no author stated]. Psychiatric medications and cytochrome P450 enzymes [handout]. 7th Annual Mayo Clinic College of Medicine Summer Course on Psychiatric Genomics: Applications for Clinical Practice; 2008 Aug 11–15; Rochester (MN)

20.

Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37(2): 171–8PubMedCrossRef

21.

Kafantaris V, Coletti DJ, Dicker R, et al. Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. J Am Acad Child Adolesc Psychiatry 2004; 43(8): 984–93PubMedCrossRef

22.

Patel NC, DelBello MP, Bryan HS, et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 289–97PubMedCrossRef

23.

Ragheb M. Ibuprofen can increase serum lithium level in lithium-treated patients. J Clin Psychiatry 1987; 48(4): 161–3PubMed

24.

Stahl SM. Essential psychopharmacology: antipsychotic agents. In: Neuroscientific basis and practical applications. 2nd ed. New York (NY): Cambridge University Press, 2000: 401–58

25.

Kowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000; 39(6): 713–20PubMedCrossRef

26.

DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adol Psychiatry 2002; 41(10): 1216–23CrossRef

27.

Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44(5): 409–17PubMedCrossRef

28.

DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 305–13PubMedCrossRef

29.

An outpatient study of the effectiveness and safety of Depakote ER in the treatment of mania/bipolar disorder in children and adolescents [online]. Available from URL: http://www.clinicaltrials.gov (Identifier NCT00067262) [Accessed 2007 Aug 13]

30.

Azorin JM, Findling RL. Valproate use in children and adolescents with bipolar disorder. CNS Drugs 2007; 21(12): 1019–33PubMedCrossRef

31.

Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression: Lamictal 692 Study Group. J Clin Psychiatry 1999; 60(2): 79–88PubMedCrossRef

32.

Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 298–304PubMedCrossRef

33.

Varghese SP, Haith LR, Patton ML, et al. Lamotrigine-induced toxic epidermal necrolysis in three patients treated for bipolar disorder. Pharmacotherapy 2006; 26(5): 699–704PubMedCrossRef

34.

Culy CR, Goa KL. Lamotrigine: a review of its use in childhood epilepsy. Pediatr Drugs 2000; 2(4): 299–330CrossRef

35.

Lonjou C, Thomas L, Ledger N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6(4): 265–8PubMed

36.

MacMillan CM, Korndorfer SR, Rao S, et al. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J Psychiatr Pract 2006 Jul; 12(4): 212–22CrossRef

37.

Wagner KD, Kowatch RA, Emslie GJ. A double-blind, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006 Jul; 163(7): 1179–86PubMedCrossRef

38.

Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006; 8(1): 15–27PubMedCrossRef

39.

DelBello MP, Findling RL, Kushner S, et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44(6): 539–47PubMedCrossRef

40.

Tramontina S, Zeni CP, Pheula G, et al. Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial. J Child Adolesc Psychopharmacol 2007; 17(1): 129–34PubMedCrossRef

41.

Topamax: full prescribing information [online]. Available from URL: http://www.topamax360.com/omn360/assets/topamax/pdf/topamax_pi.pdf#zoom=100 [Accessed 2008 Aug 25]

42.

Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63(6): 670–85CrossRef

43.

Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47(1): 9–20PubMedCrossRef

44.

Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated events. J Am Acad Child Adolesc Psychiatry 2002; 41(12): 1439–46PubMedCrossRef

45.

Kowatch RA, Suppes T, Gilfillin SK. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: a clinical case series. J Child Adolesc Psychopharm 1995; 5(4): 241–53CrossRef

46.

Kant R, Chalansani R, Chengappa KN, et al. The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder. J Child Adolesc Psychopharmacol 2004; 14(1): 57–63PubMedCrossRef

47.

Cheng-Sharron J, McGough JJ, Pataki C, et al. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14(3): 372–94CrossRef

48.

Seppala NH, Leinonen EV, Lehtonen ML, et al. Clozapine serum concentrations are lower in smoking than in nonsmoking schizophrenic patients. Pharmacol Toxicol 1999; 85(5): 244–6PubMedCrossRef

49.

Frazier J, Meyer M, Biederman J, et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999; 38(8): 960–5PubMedCrossRef

50.

Biederman J, Mick E, Wozniak J, et al. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005; 15(2): 311–7PubMedCrossRef

51.

Biederman J, Mick E, Hammerness P, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in pre-school children. Biol Psychiatry 2005; 58(7): 589–94PubMedCrossRef

52.

Pandina GJ, DelBello MP, Kushner S, et al. Risperidone for the treatment of acute mania in bipolar youth [poster presentation]. 54th Annual National Meeting of the American Academy of Child and Adolescent Psychiatry; 2007 Oct 23–28; Boston (MA)

53.

Keks NA, Culhane C. Risperidone (Risperdal): clinical experience with a new antipsychotic drug. Expert Opin Investig Drugs 1999; 8(4): 443–52PubMedCrossRef

54.

Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002; 41: 337–43PubMedCrossRef

55.

Pfeifer JC, Kowatch RA, DelBello MP. The use of antipsychotics in children and adolescents with bipolar disorders. Expert Opin Pharmacother 2007; 8(16): 2673–87PubMedCrossRef

56.

Frazier JA, Biederman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharm 2001; 11(3): 239–50CrossRef

57.

DelBello MP, Cecil KM, Adler CM, et al. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2006; 31(6): 1264–73PubMed

58.

Tohen M, Kruzhanovsky L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007 Oct; 164(10): 1547–56PubMedCrossRef

59.

Strawn J, DelBello MP. Olanzapine for the treatment of bipolar disorder in children and adolescents. Expert Opin Pharmacother 2008; 9: 1–8CrossRef

60.

DelBello MP, Findling RL, Earley WR, et al. Efficacy of quetiapine in children and adolescents with bipolar mania: a 3-week, double-blind, randomized, placebo-controlled trial. [poster presentation]. 46th Annual Meeting of the American College of Neuropsychopharmacology; 2007 Dec 9–13; Boca Raton (FL)

61.

Findling RL, Reed MD, O’Riordan MA, et al. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 2006; 45(7): 792–800PubMedCrossRef

62.

Keck Jr PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160(4): 741–8PubMedCrossRef

63.

Biederman J, Mick E, Spencer T, et al. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord 2007 Dec; 9(8): 888–94PubMedCrossRef

64.

Barnett MS. Ziprasidone monotherapy in pediatric bipolar disorder. J Adolesc Psychopharm 2004; 14: 471–7CrossRef

65.

DelBello MP, Findling RL, Wang PP, et al. Efficacy and safety of ziprasidone in pediatric bipolar disorder [poster presentation]. 48th Annual New Clinical Drug Evaluation Unit Meeting; 2008 May 27–30; Phoenix (AZ)

66.

Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005; 10(11 Suppl. 17): 1–20PubMed

67.

Biederman J, Micks E, Spencer T, et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007; 12(9): 683–9PubMed

68.

Tramontina S, Zeni CP, Pheula GF, et al. Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/ hyperactivity disorder: an open clinical trial. CNS Spectr 2007 Oct; 12(10): 758–62PubMed

69.

Correll CU, Nyilas M, Aurang C, et al. Safety and tolerability of aripiprazole in children (10–17) with mania [poster presentation]. 54th Annual National Meeting of the American Academy of Child and Adolescent Psychiatry; 2007 Oct 23–28; Boston (MA)

70.

Citrome L. Paliperidome: quo vadis? Int J Clin Pract 2007; 61(4): 653–62PubMedCrossRef

71.

Bhangoo RK, Lowe CH, Myers FS, et al. Medication use in children and adolescents treated in the community for bipolar disorder. J Child Adolesc Psychopharmacol 2003; 13(4): 515–22PubMedCrossRef

72.

Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry 2005; 66 Suppl. 3: 12–9

73.

Pavulari MN, Henry DB, Carbray JA, et al. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 2004; 82 Suppl. 1: S103–11CrossRef

74.

Pavulari MN, Henry DB, Carbray JA, et al. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol 2006; 16(3): 336–50CrossRef

75.

Kowatch RA, Sethuraman G, Hume JH, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry 2003; 53: 978–84PubMedCrossRef

76.

Soutullo CA, DelBello MP, Ochsner JE, et al. Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord 2002; 70: 323–7PubMedCrossRef

77.

Biederman J, Mick E, Spencer TJ, et al. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol 2000; 10(3): 185–92PubMedCrossRef

78.

Hammand TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63(3): 332–9CrossRef

79.

Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297(15): 1683–96PubMedCrossRef

80.

Marangell LB, Dennehy EB, Wisniewski SR, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry 2008; 69(6): 916–22PubMedCrossRef

81.

Tillman R, Geller B, Klages T, et al. Psychotic phenomenon in 257 young children and adolescents with bipolar I disorder: delusions and hallucinations (benign and pathological). Bipolar Disord 2008; 10(1): 45–55PubMedCrossRef

82.

Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44(3): 213–35PubMedCrossRef

83.

Biederman J, Spencer T, Wilens T, et al. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2004; 7: 77–97PubMedCrossRef

84.

Scheffer RE, Kowatch RA, Carmody T, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162(1): 58–64PubMedCrossRef

85.

Consoli A, Bouzamondo A, Guile JM, et al. Comorbidity with ADHD decreases response to pharmacotherapy in children and adolescents with acute mania: evidence from a metaanalysis. Can J Psychiatry 2007; 52(5): 323–8PubMed

86.

Henin A, Biederman J, Mick E, et al. Childhood antecedent disorders to bipolar disorder in adults: a controlled study. J Affect Disord 2007; 99(1–3): 51–7PubMedCrossRef

87.

DelBello MP, Kowatch RA. Pharmacological interventions for bipolar youth: developmental considerations. Dev Psychopathol 2006; 18(4): 1231–46PubMedCrossRef

88.

Saxena K, Howe M, Simeonova D, et al. Divalproex sodium reduces overall aggression in youth at risk for bipolar disorder. J Child Adolesc Psychopharmacol 2006; 16(3): 252–9PubMedCrossRef

89.

Kovacs M, Pollock M. Bipolar disorder and comorbid conduct disorder in childhood and adolescence. J Am Acad Child Adolesc Psychiatry 1995; 34: 715–23PubMedCrossRef

90.

Kutcher SP, Marton P, Kerenblum M. Relationship between psychiatric illness and conduct disorder in adolescents. Can J Psychiatry 1989; 34: 526–9PubMed

91.

Barzman DH, DelBello MP, Adler CM, et al. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavioral disorder(s). J Child Adolesc Psychopharmacol 2006; 16(6): 665–70PubMedCrossRef

92.

Barzman DH, Findling RL. Pharmacological treatment of pathologic aggression in children. Int Rev Psychiatry 2008; 20(2): 151–7PubMedCrossRef

93.

Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98(3): 247–52PubMedCrossRef

94.

Cook S, Weitzman M, Aunger P, et al. Prevalence of a metabolic phenotype in adolescents: findings from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 2003; 157: 821–7PubMedCrossRef

95.

Patel NC, Hariparsad M, Matias-Akthar M, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol 2007; 17(3): 303–11PubMedCrossRef

96.

American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27(2): 596–601CrossRef

97.

Daniels SR, Greer FR, and the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122(1): 189–208CrossRef

98.

Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163(12): 2072–9PubMedCrossRef

99.

Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008; 13(2): 383–92PubMedCrossRef

100.

Sikick L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133–45CrossRef

101.

Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 28(4): 530–5PubMedCrossRef

102.

Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry 2006; 18(1): 57–62PubMedCrossRef

103.

Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007; 17: 647–56PubMedCrossRef

104.

Chang KD. The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry 2008; 69 Suppl. 4: 4–8

105.

Geller B, Cooper TB, Zimerman B, et al. Lithium for prepubertal depressed children with family history predictors of future bipolarity: a double-blind, placebo-controlled study. J Affect Disord 1998; 51(2): 165–75PubMedCrossRef

106.

DelBello MP, Adler CM, Whitsel RM, et al. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar 1 disorder. J Clin Psychiatry 2007; 68: 789–95PubMedCrossRef

107.

Saxena K, Howe M, Simeonova D, et al. Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder. J Child Adolesc Psychopharmacol 2006; 16(3): 252–9PubMedCrossRef

108.

Chang KD, Dienes K, Blasey C, et al. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. J Clin Psychiatry 2003; 64(8): 936–42PubMedCrossRef

109.

Findling RL, Frazier TW, Youngstrom EA. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J Clin Psychiatry 2007; 46(7): 831–9

110.

Rey JM, Walter G, Soh N. Complementary and alternative medicine (CAM) treatments and pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2008 Apr; 47: 364–8PubMedCrossRef

111.

Mrazek DA. Current applications of clinical genetic testing for psychiatric practice. Minn Med 2007; 90(1): 42–3PubMed

112.

Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry 2005; 162: 397–8PubMedCrossRef

113.

Carlson GA, Bromet EJ, Driessens C, et al. Age at onset, childhood psychopathology, and 2-year outcome in psychotic bipolar disorder. Am J Psychiatry 2002; 159: 307–9PubMedCrossRef

114.

Birmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psych 2006; 63: 175–83CrossRef

115.

Patel NC, DelBello MP, Cecil KM, et al. Temporal changes in N-acetyl-aspartate concentrations in adolescents with bipolar disorder depression treated with lithium. J Child Adolesc Psychopharmacol 2008 Apr; 18(2): 132–9PubMedCrossRef

116.

Atmaca M, Ozdemir H, Cetinkaya S, et al. Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine. J Psychiatr Res 2007; 41(10): 821–7PubMedCrossRef

117.

Chang KD, Wagner C, Garrett A, et al. A preliminary functional magnetic resonance imaging study of prefrontal-amygdalar activation changes in adolescents with bipolar depression treated with lamotrigine. Bipolar Disord 2008; 10(3): 426–31PubMedCrossRef

118.

DelBello MP, Hansenman D, Adler CM, et al. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry 2007; 164(4): 582–90PubMedCrossRef

Title: Pharmacotherapy of bipolar disorder in children and adolescents
Recent progress
Authors: Jonathan C. Pfeifer
Robert A. Kowatch
Dr Melissa P. DelBello
Publication date: 01-07-2010
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 7/2010
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/11533110-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacotherapy of bipolar disorder in children and adolescents

Recent progress

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2010

Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine

Medication errors in psychiatry

Antidepressant-induced hyperprolactinaemia

Escitalopram in the treatment of major depressive disorder in adolescent patients

Lafora disease

Assessment of abuse potential of benzodiazepines from a prescription database using ‘doctor shopping’ as an indicator